Quality of life in patients with head and neck cancer receiving targeted or multimodal therapy - Update of the EORTC QLQ-H&N35, Phase i

Head and Neck

Volumn 35, Issue 9, 2013, Pages 1331-1338

  Singer, Susanne ^a   Arraras, Juan I ^b   Baumann, Ingo ^c   Boehm, Andreas ^a   Chie, Wei Chu ^d   Galalae, Razvan ^e   Langendijk, Johannes A ^f   Guntinas Lichius, Orlando ^g   Hammerlid, Eva ^h   Pinto, Monica ⁱ   Nicolatou Galitis, Ourania ^j   Schmalz, Claudia ^k   Sen, Mehmet ^l   Sherman, Allen C ^m   Spiegel, Karin ^g   Verdonck De Leeuw, Irma ^g   Yarom, Noam ⁿ   Zotti, Paola ^o   Hofmeister, Dirk ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Universidad Pública de Navarra   (Spain)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e ST JOSEF HOSPITAL   (Germany)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j UNIVERSITY OF ATHENS   (Greece)

^k UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^l ST JAMES S INSTITUTE OF ONCOLOGY   (United Kingdom)

^m UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

ⁿ TEL AVIV UNIVERSITY   (Israel)

^o CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

more..

Author keywords

chemoradiation; head and neck neoplasms; larynx; multimodal therapies; oral cavity; pharynx

Indexed keywords

ADJUVANT CHEMORADIOTHERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL (TOPIC); HEAD AND NECK CANCER; HEALTH CARE PERSONNEL; HUMAN; INTERVIEW; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

CHEMORADIATION; HEAD AND NECK NEOPLASMS; LARYNX; MULTIMODAL THERAPIES; ORAL CAVITY; PHARYNX;

AGED; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84883051141     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23127     Document Type: Article

References (44)

1. Bjordal K, Ahlner-Elmqvist M, Tollesson E, et al. Development of a European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients. EORTC Quality of Life Study Group. Acta Oncol 1994; 33: 879-885.
2. Bjordal K, de Graeff A, Fayers PM, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 2000; 36: 1796-1807.
3. Singer S, Wollbrück D, Wulke C, et al. Validation of the EORTC QLQ-C30 and EORTC QLQ-H&N35 in patients with laryngeal cancer after surgery. Head Neck 2009; 31: 64-76.
4. Zotti P, Lugli D, Vaccher E, Vidotto G, Franchin G, Barzan L,. The EORTC quality of life questionnaire-head and neck 35 in Italian laryngectomized patients. European organization for research and treatment of cancer. Qual Life Res 2000; 9: 1147-1153.
5. Jensen K, Jensen AB, Grau C,. A cross sectional quality of life study of 116 recurrence free head and neck cancer patients. The first use of EORTC H&N35 in Danish. Acta Oncol 2006; 45: 28-37.
6. Sherman AC, Simonton S, Adams DC, Vural E, Owens B, Hanna E,. Assessing quality of life in patients with head and neck cancer: cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Head and Neck module (QLQ-H&N35). Arch Otolaryngol Head Neck Surg 2000; 126: 459-467.
7. Hammerlid E, Silander E, Hörnestam L, Sullivan M,. Health-related quality of life three years after diagnosis of head and neck cancer-a longitudinal study. Head Neck 2001; 23: 113-125.
8. Mehanna HM, Morton RP,. Patients' views on the utility of quality of life questionnaires in head and neck cancer: a randomised trial. Clin Otolaryngol 2006; 31: 310-316.
9. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
10. Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007; 25: 2191-2197.
11. Op de Coul BM, Ackerstaff AH, van As CJ, et al. Quality of life assessment in laryngectomized individuals: do we need additions to standard questionnaires in specific clinical research projects? Clin Otolaryngol 2005; 30: 169-175.
12. Hanna E, Sherman A, Cash D, et al. Quality of life for patients following total laryngectomy vs chemoradiation for laryngeal preservation. Arch Otolaryngol Head Neck Surg 2004; 130: 875-879.
13. Guntinas-Lichius O, Rühlow S, Veelken F, Klussmann JP,. Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel. J Cancer Res Clin Oncol 2009; 135: 901-908.
14. Brizel DM, Murphy BA, Rosenthal DI, et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 2008; 26: 2489-2496.
15. Abdel-Wahab M, Abitbol A, Lewin A, Troner M, Hamilton K, Markoe A,. Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma. Am J Clin Oncol 2005; 28: 359-366.
16. Ackerstaff AH, Balm AJ, Rasch CR, et al. First-year quality of life assessment of an intra-arterial (RADPLAT) versus intravenous chemoradiation phase III trial. Head Neck 2009; 31: 77-84.
17. Levendag PC, Teguh DN, Voet P, et al. Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship. Radiother Oncol 2007; 85: 64-73.
18. Poulsen MG, Riddle B, Keller J, Porceddu SV, Tripcony L,. Predictors of acute grade 4 swallowing toxicity in patients with stages III and IV squamous carcinoma of the head and neck treated with radiotherapy alone. Radiother Oncol 2008; 87: 253-259.
19. Vokes EE, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003; 21: 320-326.
20. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715.
21. Rosenthal DI, Lewin JS, Eisbruch A,. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 2006; 24: 2636-2643.
22. Huguenin P, Glanzmann C, Taussky D, Lütolf UM, Schmid S, Moe K,. Hyperfractionated radiotherapy and simultaneous cisplatin for stage-III and -IV carcinomas of the head and neck. Long-term results including functional outcome. Strahlenther Onkol 1998; 174: 397-402.
23. Mittal BB, Kepka A, Mahadevan A, et al. Tissue/dose compensation to reduce toxicity from combined radiation and chemotherapy for advanced head and neck cancers. Int J Cancer 2001; 96 Suppl: 61-70.
24. McQuellon RP, Moose DB, Russell GB, et al. Supportive use of megestrol acetate (Megace) with head/neck and lung cancer patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2002; 52: 1180-1185.
25. Mantovani G, Massa E, Astara G, et al. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. Oncol Rep 2003; 10: 197-206.
26. Haraf DJ, Rosen FR, Stenson K, et al. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res 2003; 9 (16Pt1): 5936-5943.
27. Arias de la Vega F, Domínguez Domínguez MA, Manterola Burgaleta A, et al. Concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas. Preliminary results of a phase II, single-institutional trial. Clin Transl Oncol 2005; 7: 60-65.
28. Bensadoun RJ, Bénézery K, Dassonville O, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 2006; 64: 983-994.
29. Guntinas-Lichius O, Appenrodt S, Veelken F, Krug B,. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer. Laryngoscope 2006; 116: 613-618.
30. Gillespie MB, Day TA, Sharma AK, Brodsky MB, Martin-Harris B,. Role of mitomycin in upper digestive tract stricture. Head Neck 2007; 29: 12-17.
31. Corry J, Poon W, McPhee N, et al. Randomized study of percutaneous endoscopic gastrostomy versus nasogastric tubes for enteral feeding in head and neck cancer patients treated with (chemo)radiation. J Med Imaging Radiat Oncol 2008; 52: 503-510.
32. Fabrício Vde C, Amado F, Del Giglio A,. Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas. Sao Paulo Med J 2008; 126: 63-66.
33. Hui EP, Ma BB, Leung SF, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009; 27: 242-249.
34. Brown B, Diamantopoulos A, Bernier J, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health 2008; 11: 791-799.
35. Finizia C, Hammerlid E, Westin T, Lindström J,. Quality of life and voice in patients with laryngeal carcinoma: a posttreatment comparison of laryngectomy (salvage surgery) versus radiotherapy. Laryngoscope 1998; 108: 1566-1573.
36. Nijdam WM, Levendag PC, Noever I, Schmitz PI, Uyl-de Groot CA,. Longitudinal changes in quality of life and costs in long-term survivors of tumors of the oropharynx treated with brachytherapy or surgery. Brachytherapy 2008; 7: 343-350.
37. Roberge C, Tran M, Massoud C, et al. Quality of life and home enteral tube feeding: a French prospective study in patients with head and neck or oesophageal cancer. Br J Cancer 2000; 82: 263-269.
38. D'Antonio LL, Zimmerman GJ, Cella DF, Long SA,. Quality of life and functional status measures in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 1996; 122: 482-487.
39. Bjordal K, Hammerlid E, Ahlner-Elmqvist M, et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 1999; 17: 1008-1019.
40. van Herpen CM, Mauer ME, Mesia R, et al. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). Br J Cancer 2010; 103: 1173-1181.
41. Jensen K, Bonde Jensen A, Grau C,. The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires. Radiother Oncol 2006; 78: 298-305.
42. Ho KF, Farnell DJ, Routledge JA, et al. Comparison of patient-reported late treatment toxicity (LENT-SOMA) with quality of life (EORTC QLQ-C30 and QLQ-H&N35) assessment after head and neck radiotherapy. Radiother Oncol 2010; 97: 270-275.
43. Jensen K, Lambertsen K, Torkov P, Dahl M, Jensen AB, Grau C,. Patient assessed symptoms are poor predictors of objective findings. Results from a cross sectional study in patients treated with radiotherapy for pharyngeal cancer. Acta Oncol 2007; 46: 1159-1168.
44. Johnson C, Aaronson N, Blazeby JM, et al. Guidelines for developing questionnaire modules. 4th ed. Brussels: EORTC, 2011.